title: Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.
abstract: Cardiometabolic disorders including obesity, diabetes and cardiovascular disease are among the most severe health problems worldwide. DPP4 enzymatic inhibitors were first developed as anti-diabetic reagents which preserve incretin hormones and promote post-prandial insulin secretion. It's been shown in animal studies that incretin-based therapy has a beneficial effect on cardiovascular disease. Recent studies demonstrated novel non-catalytic functions of DPP4 that may play a role in cardiometabolic disease. Although the role of DPP4 inhibition-mediated incretin effects has been well-reviewed, little information of its incretin-independent actions was introduced in cardiometabolic disease. In the current review, we will summarize the catalytic dependent and independent effects of DPP4 inhibition on cardiometabolic disease.
authors.affiliation: Department of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei 434023, PR China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Gong
authors.affiliation: Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: srajagopalan@medicine.umaryland.edu.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Rajagopalan
authors.affiliation: Department of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei 434023, PR China; Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: jzhong@medicine.umaryland.edu.
authors.forename: Jixin
authors.initials: J
authors.lastname: Zhong
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D006801:Humans; D054795:Incretins / Q000378:metabolism*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D054795:Incretins; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4
keywords: Cardiometabolic disease; DPP4; Diabetes; GLP-1; Incretin